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The binding of mithramcyin A to d(ACCCGGGT)2 has been investigated by one- and two.dimensional ‘H NMR spectroscopy. Titration of the 
drug into the octamcr solution results in loss of the oligonucleotide C: symmetry at stoichiometric ratios less than 4 drug molecules per duplex. 
However, at a ratio of4:I (drug/duplex). the Cz symmetry of the oligonucleotide is restored. From these data it isevident that more than onecomplex 
forms at ratios less than 4: I while only one complex predominates at the ratio 4: I. This is the first report of a DNA octamer which binds 4 large 
drug molecules. These results are compared to those we have recently reported for mithramycin binding to d(ATGCAT),, where only a single. bound 
complex is observed. with a stoichiometry of 2: I. 
Mithramycin: Drug-DNA interaction. ‘H NMR 
1. INTRODUCTION 
Drugs based on the aureolic acid backbone have, 
over the years, shown many atypical binding properties 
with DNA [I]. This family of relatively large drugs (mo- 
lecular weight ca. 1200 g/mol). that includes chromomy- 
tin [2,3]. mithramycin [4] and olivomycin [5], binds to 
DNA in the presence of divalent cations and shows a 
preference for GC base pairs. Recent NMR studies with 
short oligonucleotides have demonstrated that mithra- 
mycin and chromomycin bind to DNA as dimers in the 
minor groove [2-41. 
Recently we have shown that chromomycin prefers 
5’-GC-3’ over 5’-GC-3’ sites [3]. In addition. it is known 
that one of the most favored sites is a 5’-Ccc-3 se- 
quence [6]. Here we present data on the association of 
mithramycin A in the presence of Mg” with 
d(ACCCGGGT), [7]? a sequence that contains the less 
favored 5’-CG-3’ sequence at the center of the oligonu- 
cleotide and the highly favored 5’-CCC-3’ sequence off- 
center. We are now able to demonstrate that an oligonu- 
cleotide with just eight base pairs binds four molecules 
of mithramycin and does so in a manner that retains the 
original symmetry of the oligonucleotide when all the 
binding sites are occupied. This represents the first ex- 
ample of such a short DNA oligonucleotide binding 
four large drug molecules. 
The ‘H NMR spectra of a drug-oligonucleotide com- 
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plex can be very complicated, particularly if the symme- 
try of a self-complementary sequence is removed by 
drug binding and/or there is a mixture of free and drug- 
associated oligonucleotide. There are, however. two re- 
gions of the NMR spectrum that are excellent indicators 
of the nature and extent of the drug association. The 
imino proton region is ideal for investigating drug bin- 
ding because it is well separated from all other nucleo- 
tide signals and because each base pair contributes only 
one resonance to this region. The non-exchangeable cy- 
tosine H5 and H6 base protons are less frequently used 
for this purpose but they can be separated from other 
base resonances if the scalar coupling between these two 
protons is exploited. We have used the 2D HOHAHA 
experiment [8] to show how the number of distinct cyto- 
sine resonances changes as the mithramycinl 
d(ACCCGGGT), ratio is altered. 
2. MATERIALS AND METHODS 
Mithramycin A, produced by Slrepprotr?_cce.sp/icolus, was purchased 
from Sigma (St. Louis, MO) and used without further purification. 
The octamer d(ACCCGGGT)2 was synthesized and purified as de- 
scribed previously [7]. All NMR samples were I mM in duplex 
d(ACCCGGGT): in 20 mM phosphate. 40 mM NaCI, 0.05 mM 
EDTA. pH 7.2. Dsplex concentration was determined spectrophoto- 
metrically. assuming a duplex molar extinction cocficicnt of 103 000.’ 
M-cm which was dctermincd by phosphate analysis. The mithramy- 
cin-d(ACCCGGGT)2 complex was made by solubilizing !yophilized 
aliquots of mithramycin in the d(ACCCGGGT)2 solution that had 
!vlMg” in slight excess of a 4:1 molar ratio of Mg”/d(ACCCGGGT),. 
Theconcentration of the stock solution of mitbraniycin WCS calculated 
with a molar extinction cocflicient of I3 000/M-cm (in a I M NaCI, 
100 mM borate buffer, pH 8.0, at room temperature) which we dcter- 
mined spectrophotometrically from the dry weight. NMR experiments 
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were carried out on a Varian VXRSOOS spectrometer. Experimental 
details are given in the figure legends. 
3. RESULTS 
Taking into consideration the symmetry of 
d(ACCCGGGT),, we expected only three guanine 
imino proton resonances in the lowfield region of the 
spectrum of H,Q. These three resonances are shown in 
Fig. 1A. The thymine imino proton resonance is not 
observed at 1Y’C because of rapid exchange with the 
solvent at the terminal base pairs. For similar symmetry 
considerations, only three H5/H6 crosspeaks are obser- 
ved in the HOHAHA spectrum of the octamer obtained 
in D?O, illustrated in Fig. 2A (the splitting of each peak 
due to the 7 Hz coupling constant is evident in the F2 
dimension). 
On addition of mithramycin to d(ACCCGGGT)? in 
the ratio 1:l (drug molecules per duplex), at least eight 
additional imino resonances are observed in the region 
11-14 ppm (Fig. 1B). It has been shown recently that 
both chromomycin and mithramycin bind to self-com- 
plementary DNA duplexes with retention of C, symme- 
try [24]. If the binding site is at the center of the 
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Fig. I. 500 MHz ‘H NMR spectra of d(ACCCGGGT): and the mi- 
thramycin-d(ACCCGGGT),-Mg’+ ternary complex I mM in DNA 
duplex. in 20 mM sodium phosphalc. 40 mM NaCI. 0.05 mM EDTA. 
pH 7.2 in 10% D:OiSO% H:O. All spectra were taken at 15°C. (A) 0: I. 
(IS) I : I, (C) 2: I. (D) 4: I, mithramycin/d(ACCCGGGTJJ. The water 
resonance was suppressed by a I r 3-r 3 r I ‘Sequence. Each spectrum 
required I28 scans over a swccpwidth of 12.5 kHz and r was set at 
On further addition of mithramycin to 
d(ACCCGGGT)? to a ratio of 2: 1 the original guanine 
imino resonances have disappeared and there are at 
!east nine peaks in the region 11-14 ppm (Fig. 1C). each 
distinct from the three original resonances of free DNA. 
In addition, a third resonance appears in the 16.5-I 5.5 
ppm spectral region. The absence of free DNA at this 
ratio can be seen more clearly in the HOHAHA spec- 
trum for the 2:l ratio (Fig. 20 Furthermore. the rela- 
tive intensities of the new crosspeaks have changed sub- 
stantially from those observed at the ! .5: 1 ratio. 
9G ps. At a 4: 1 drug/duplex ratio here arc only three distinct 
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Fig. 2. SO0 MHz ‘H 2D HOHAHA spectra of d(ACCCCGGT)Z and 
the mithramycin-d(ACCCGGGT):-Mg’* ternary complex;. I mM in 
DNA duplex in 20 mM sodium phosphate. 40 mM NaCI. 0.05 mM 
EDTA. pH 7.2 in 99.996% D,O. All spectra were taken at 20°C. (A) 
0:l. (B) 1 S: I. (C) 2: I 1 (D) 4: I. mithramycinld(ACCCGGGT)2. Each 
data set consisted of 256 complex increments. 2K points per FID over 
a sweep width of 4.5 kHz. The data set was zero filled to a size of I K 
x 2K real points and each dimension was apodized with a 60 degree 
shifted sinebell. 
d(ACCCGGGT)! duplex, as in all previous studies, 
then only three additional imino resonances are expec- 
ted. The two resonances between 16.5 and 15.5 ppm 
arise from one phenolic prcton of each of the bound 
mithramycin molecules. The other phenolic proton is in 
fast exchange with water and has not been observed in 
any previous NMR spectra of chromomycin or mithra- 
mycin complexes with DNA [2-4]. When the binding 
site is at the center of a symmetrical duplex. only one 
phenolic proton resonance is observed. The presence of 
two phenolic resonances in unequal ratios in combina- 
tion with the appearance of at least eight additonal 
guanine imino protons suggests that at a drug/duplex 
ratio of 1: 1 there are at least two binding sites. for 
example at 5’-CCC3 and 5’-CCG-3’. similar effects can 
also be seen in the HOHAHA data at a drug/duplex 
ratio of 1.5 (Fig. 2B). Here a small amount of free DNA 
can be discerned, along with many new crosspeaks. 
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Volume 259, numhr 2 FEES LETTERS September 199 1 
guanine imino proton resonances, which suggests that 
the original symmetry of the duplex has been restored. 
Also, there are only two drug phenolic proton resonan- 
ces, one of which appeared at the 2: 1 drug/duplex ratio. 
Taken together, these two observations are consistent 
with binding of two mithramycin dimers at two equiva- 
lent off-center sites on d(ACCCGGGT&. A small 
shoulder on the 15.2 ppm peak suggests the possibility 
of some heterogeneity in the binding sites and requires 
furt!ler investigation, We note that this shoulder cannot 
arise from free drug since its phenolic proton resonates 
at 18 ppm (data not shown). The restoration of the 
original duplex symmetry is confirmed by the presence 
of only three cytosine H5/H6 crosspeaks in the HO- 
HAHA spectrum at 4:1 (Fig. 2D). 
The large number of imino proton resonances and 
cytosine crosspeaks is inconsistent with a single binding 
site at drug/duplex ratio less than 2: 1. One might ac- 
count for the extra peaks by a mixture of free duplex, 
duplex bound by one drug dimer and duplex bound by 
two drug dimers. However, the imino proton and HO- 
HAHA spectra clearly show that there is no 4: 1 complex 
present at drug/duplex ratios less than 1.5: 1 and that 
there is no free duplex at ratios of 2:1 or greater. 
4. CONCLUSIONS 
We have sown that the octamer duplex 
d(ACCCGGGT)2 can bind as many as four molecules 
of mithramycin and effectively double its molecular 
weight. Results from the titrations establish that there 
is a variety of binding sites at ratios of drugs per duplex 
less than 4:l. The occupancy of these binding sites is 
dependent on the amount of added drug. In addition to 
the anttcipated drug-drug interactions within each 
dimer, these results imply that dimer-dimer interactions 
must also play a role in determining the exact binding 
sites of the four mithramycin molecules on the octamer. 
Hence, the binding sites observed at the intermediate 
ratios, but not at the 4:l ratio, must reflect differences 
in the preferred binding site prior to saturation. Presum- 
ably, at saturation, binding sites closer to the center are 
less favorable because of Van der Waal’s interactions 
between dimers. Preliminary 2D NOESY spectra indi- 
cate that the binding site at the 4:1 ratio is in the minor 
groove and spans all four base pairs making up half of 
the duplex, suggesting that dimerdimer contact is quite 
close. A more detailed 2D NMR study is underway to 
accurately determine the binding site and to ascertain 
whether binding of a second dimer entials relocation of 
the binding sites present at the 2:1 drug duplex ratio. 
A thorough analysis of the mithramycin- octamer com- 
plex structure should assist in determining the physical 
basis of the preference for the -CCC- binding site. 
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